Galecto Inc. (NASDAQ: GLTO)
$0.57
-0.0240 ( -4.06% ) 131.0K
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
Market Data
Open
$0.57
Previous close
$0.59
Volume
131.0K
Market cap
$15.45M
Day range
$0.55 - $0.61
52 week range
$0.46 - $3.70
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-k | Annual reports | 87 | Mar 08, 2024 |
4 | Insider transactions | 1 | Jan 05, 2024 |
4 | Insider transactions | 1 | Jan 05, 2024 |
4 | Insider transactions | 1 | Jan 05, 2024 |
8-k | 8K-related | 12 | Dec 21, 2023 |
10-q | Quarterly Reports | 65 | Nov 06, 2023 |
8-k | 8K-related | 14 | Oct 23, 2023 |
8-k | 8K-related | 12 | Oct 02, 2023 |
8-k | 8K-related | 14 | Sep 26, 2023 |
4 | Insider transactions | 1 | Aug 17, 2023 |